These compounds have demonstrated significant efficacy against multiple cancer cell types, including breast and prostate cancer, the company said.
“This Chinese patent reinforces the promise of our lead molecule and the vital work being done by our team at Sathgen Therapeutics to develop innovative therapies for some of the most pressing medical needs worldwide,” Dr Sangeeta Srivastava, Executive Director, Godavari Biorefineries, said.On July 3, the company announced that its European patent for a novel anti-cancer molecule had been successfully validated in Spain, the United Kingdom, and as a unitary patent across multiple European Union member states.
Godavari Biorefineries in its fourth quarter results posted a 10.37% YoY rise in consolidated net profit to ₹71.93 crore in Q4 FY25. This came despite a 5.80% decline in revenue from operations, which stood at ₹579.50 crore.Profit before tax (PBT) rose 5.23% YoY to ₹95.74 crore, while EBITDA dipped slightly by 2.17% to ₹121.7 crore. However, the EBITDA margin improved to 21%, up from 20.2% a year ago, helped by a better product mix and cost efficiencies.
The company is primarily involved in the renewable chemicals and
biofuels industry, and its product portfolio includes bio-based chemicals, sugar, various grades of ethanol, and power.
Meanwhile, Sathgen Therapeutics works on developing novel cancer and antiviral therapies.
The company’s shares are trading at ₹327.43, up 5% or ₹15.59 on the NSE. The stock has jumped as much as 30% in the past month.
